Background
Primary gastrointestinal natural killer (NK)/T‐cell lymphoma (PGINKTL) is a rare T‐/NK‐cell lymphoma subtype, and the clinical features and survival outcomes remain largely unknown.
Methods
To summarize the clinical features and survival outcomes of PGINKTL, PGINKTL cases diagnosed at our hospital from May 1999 to December 2020 were reviewed; and the clinical data, information on treatment strategies, and survival were collected. Survival analysis was performed using the Kaplan–Meier method and multivariable Cox proportional hazards regression. We constructed a nomogram to visualize the survival prediction of PGINKTL. The discriminative ability and calibration of the nomogram for prediction were tested using the concordance index (C‐index) and calibration plots.
Results
The cohort included 81 cases, the median age was 36 years (range, 7–80 years), and the male‐to‐female ratio was 1.7:1. The most common clinical symptom at the time of diagnosis was abdominal pain (71.6%). The most common lesion site was the colon (59.3%). During a median follow‐up period of 37.7 months, the median overall survival (OS) time of 81 patients was 4.0 months (95% confidence interval [CI], 3.1–4.9 months), and the 2‐year OS rate was 30.7% (95% CI, 20.3%–40.1%). The multivariate analyses indicated that patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score ≥2, serum lactic dehydrogenase (LDH) level ≥ the upper limit normal (ULN), and perforation had worse OS. We used these data to establish a nomogram to predict survival for PGINKTL. The nomogram displayed good accuracy, with a C‐index of 0.726.
Conclusion
The clinical features and poor outcomes of PGINKTL, which is a rare and fatal lymphoma type, are presented. The proposed nomogram provides an individualized estimate of survival for these patients. In the future, the study focused on exploring a better treatment strategy to improve survival is required in PGINKTL.
There is currently little available evidence about the causal relationship between HIV infection and Coronavirus disease 2019 (COVID-19), and these relationships may differ across populations and socioeconomic contexts. In this study, two-sample Mendelian randomisation analyses were conducted using summary-level data from genome-wide association studies of the European ancestry population. We initially examined the causality from HIV-1 infection to the spectrum of COVID-19 [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, COVID-19 hospitalisation, and very severe respiratory disease]. Then we additionally tested the causality from socioeconomic-position (SEP) indicators (educational attainment and household income) to HIV-1 infection, and from educational attainment and household income to the spectrum of COVID-19. We also tested the causality from HIV-1 infection to body height as a negative control. Null causality from HIV-1 infection to the spectrum of COVID-19 was found. The risk of HIV-1 infection significantly decreased as educational attainment and household income increased. Higher educational attainment was causally associated with lower odds of the spectrum of COVID-19. Higher household income was causally associated with lower odds of COVID-19 hospitalisation and very severe respiratory disease. Negative control shared a similar result with the estimates between HIV-1 infection and the spectrum of COVID-19. We concluded that HIV-1 infection was not causally associated with SARS-CoV-2 infection, COVID-19 hospitalisation, and very severe respiratory disease. Reduction in socioeconomic inequality could potentially ameliorate COVID-19-related and HIV-related health inequities.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.